Phosphorus

Takara Bio USA Wins EU Opposition Hearing, Revoking Jumpcode Genomics’ NGS Library Enrichment Patent

Retrieved on: 
Monday, December 11, 2023
Stem Cells, Medical Supplies, Biotechnology, Other Health, Health, Health Technology, Other Science, Medical Devices, Research, Genetics, Science, Small RNA, A-DNA, European Patent Convention, Library, RNA, CRISPR, RNA-Seq, Hearing, Takara Holdings, Patent, Phosphorus

Takara Bio USA, Inc. today announced that it has once again prevailed in its second patent dispute with Jumpcode Genomics, Inc.

Key Points: 
  • Takara Bio USA, Inc. today announced that it has once again prevailed in its second patent dispute with Jumpcode Genomics, Inc.
  • Following a hearing before the Opposition Division of the European Patent Office on November 28, the European Patent Office revoked Jumpcode’s patent in its entirety, with no claims allowed.
  • This contrasts with Jumpcode’s earlier challenge to Takara Bio USA’s European Patent (EP3105325), which the European Patent Office upheld following a similar hearing last year.
  • This latest decision reinforces the strength of Takara Bio USA’s European patent and portfolio, which supports some of our most innovative RNA-seq technologies,” said Carol Lou, President & CEO of Takara Bio USA.

Alto Neuroscience Announces Data from Presentations at the 62nd Annual Meeting of the American College of Neuropsychopharmacology

Retrieved on: 
Thursday, December 7, 2023
Mental Health, Technology, Neurology, Clinical Trials, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Artificial Intelligence, Brain, Schizophrenia, Depression, Electroencephalography, Safety, Deficit spending, Dean (education), Grammatical mood, PD, Clinical trial, Data, Patient, American College, American College of Neuropsychopharmacology, Cross, DSM-IV codes, MADRS, Cognition, Cyclothymia, MD, Harvard Medical School, Translational research, Massachusetts General Hospital, ERP, Neuroscience, EEG, Mental health, Biomarker, MDD, Medical imaging, Phosphorus, Medical device, Pharmaceutical industry, Alto

Alto Neuroscience, Inc. today announced details from three presentations on clinical development programs presented at the 62nd annual meeting of the American College of Neuropsychopharmacology (ACNP) that took place in Tampa, Florida, from December 3-6, 2023.

Key Points: 
  • Alto Neuroscience, Inc. today announced details from three presentations on clinical development programs presented at the 62nd annual meeting of the American College of Neuropsychopharmacology (ACNP) that took place in Tampa, Florida, from December 3-6, 2023.
  • Alto’s data demonstrate advancements in biomarker identification for precision psychiatry and the potential to improve upon the trial-and-error approach to mental health treatment.
  • The company’s AI-enabled Precision Psychiatry Platform™ is designed to predict clinical response and match each patient to the right Alto product candidate through identifying, and prospectively replicating, brain biomarkers by analyzing data generated from EEG activity, neurocognitive task performance, wearable devices, and other measures.
  • Additionally, Alto is advancing ALTO-101 into a Phase 2 proof of concept study in patients with cognitive impairment associated with schizophrenia, with topline data expected in 2025.

Phosphoric acid (CAS 7664-38-2) Global Market Research Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 6, 2023
Chemicals, Plastics, Manufacturing, CAS, Fertilizer, Phosphorus, Phosphoric

The "Phosphoric acid (CAS 7664-38-2) Global Market Research Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Phosphoric acid (CAS 7664-38-2) Global Market Research Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Phosphoric acid.
  • The fifth chapter deals with Phosphoric acid market trends and forecast, distinguish Phosphoric acid manufacturers and suppliers.
  • The Phosphoric acid global market report key points:

Medefil Announces Availability of FDA-Approved Emergency Syringes, Atropine Sulfate Injection, USP, and 10% Calcium Chloride Injection, USP

Retrieved on: 
Monday, December 4, 2023
Other Manufacturing, Medical Devices, Medical Supplies, FDA, Manufacturing, Managed Care, Health, Pharmaceutical, General Health, Calcium chloride, Plasma, Hypocalcemia, ANDA, USP, Pharmaceutical industry, Phosphorus

Medefil, Inc., a domestic manufacturer of injectable products, has announced availability of its FDA-approved ANDA products, Atropine Sulfate Injection, USP, 1 mg per 10 mL (0.1 mg/mL), and 10% Calcium Chloride Injection, USP, 1000 mg per 10 mL (100 mg/mL).

Key Points: 
  • Medefil, Inc., a domestic manufacturer of injectable products, has announced availability of its FDA-approved ANDA products, Atropine Sulfate Injection, USP, 1 mg per 10 mL (0.1 mg/mL), and 10% Calcium Chloride Injection, USP, 1000 mg per 10 mL (100 mg/mL).
  • These products are currently listed on the FDA drug shortage list and are available immediately for purchase from Medefil through national wholesalers.
  • Atropine Sulfate Injection, USP, is used for temporary blockade of severe or life-threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.
  • 10% Calcium Chloride Injection, USP is used for the treatment of hypocalcemia in those conditions requiring a prompt increase in plasma calcium levels.

ŌURA Reaches Milestone of 600+ Partnerships and Integrations as It Builds a Large-Scale Ecosystem

Retrieved on: 
Thursday, November 30, 2023
Software, Biometrics, Biotechnology, General Health, Health, Health Technology, Technology, Other Health, Stress management, Woman, Behavior, Flexible, Entrepreneurship, CGM, Algorithm, Ecosystem, Cycle track, Dashboard, FSA, Growth, API, IOS, Temperature, Health savings account, Abdominal obesity, Flexible spending account, Tag, HDL, Fertility, Menopause, Oura Health, Life, Science, Meditation, Chart, Natural Cycles, Menstrual cycle, Obstetrics, DSM-IV codes, PCOS, Skin temperature, Community, Blood, Currency strap, Partnership, Himawari (satellites), Education, Hypertension, Research, Apple Watch, Learning, HSA, Pregnancy, Metabolism, FDA, Chronotype, Diary, Ready, Set, PrEP, Mindfulness, Thrive Global, Phosphorus, Mobile phone, Birth control, Pharmaceutical industry, Nursing, Medical device, Sleep, Oura, Headspace, Activity, Noom, Strava

We’ve been steadily building a strong partnership ecosystem and adding world-class features into the ŌURA experience,” said Tom Hale, CEO.

Key Points: 
  • We’ve been steadily building a strong partnership ecosystem and adding world-class features into the ŌURA experience,” said Tom Hale, CEO.
  • “ŌURA is becoming an iconic, global brand that is changing the way we think about long-term health and healthspan.
  • ŌURA is doubling down in specific focus areas with partners across several sectors including women’s health, metabolic health, behavioral health, and fitness and lifestyle.
  • These integrations represent a significant portion of new ŌURA members; additionally, ŌURA members who use Natural Cycles are the highest retaining of all ŌURA cohorts.

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

Retrieved on: 
Friday, November 17, 2023
FDA, Pharmaceutical, Health, Medicine, Vomiting, Digoxin, Osteoporosis, Woman, Urine, Antares, NYSE, Bone disease, Calcium, Spine, Prednisone, Constipation, Allergy, History, IQVIA, Patient, Arthralgia, Medication, TEVA, Fracture, Muscle weakness, System, Blood, Tongue, Vitamin, Bone tumor, Nausea, Kidney, Pain, Swelling, Osteosarcoma, Skin, Rat, TASE, Injection, Face, Blood pressure, Generic drug, Dietary supplement, Pharmaceutical industry, Vaccine, Birth control, Injection moulding, Medical imaging, Poultry farming, Phosphorus, Teriparatide, Teva

Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States.

Key Points: 
  • Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States.
  • Currently, 1 in 12 generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
  • Teva’s generic equivalent of Forteo® (teriparatide injection) utilizes the Antares Pharma, Inc. multi-dose pen device.
  • Teriparatide injection can lessen the chance of broken bones (fractures) in the spine and other bones in postmenopausal women with osteoporosis.

New Study Finds Significant Impact of Plant-Based Diets on Chronic Kidney Disease Patients

Retrieved on: 
Friday, December 15, 2023
Diet, Chronic kidney disease, Disease, National Kidney Foundation, Research, NKF, AJKD, MHS, Risk, Mortality, Vegetable, Patient, Plant, CKD, Kidney, MPH, Survival, Phosphorus, Public health, Quality of life, Soft drink, Dietary supplement, Pharmaceutical industry, MD, Doctor of Philosophy

NKF's AJKD study reveals that a healthy plant-based diet will reduce the risk of all-cause mortality in CKD patients.

Key Points: 
  • NKF's AJKD study reveals that a healthy plant-based diet will reduce the risk of all-cause mortality in CKD patients.
  • This study suggests that plant-based diets can be a viable and beneficial dietary option for CKD patients.
  • It also emphasizes the importance of dietary quality by distinguishing between overall plant-based diets, healthy plant-based diets, and unhealthy plant-based diets.
  • The study, which involved 2,539 participants with CKD from the Chronic Renal Insufficiency Cohort (CRIC) study, conducted between 2003 and 2008, sheds light on the impact of dietary choices in CKD patients.

Study: Extreme Rainfall Increases Ag Nutrient Runoff, Conservation Strategies Can Help

Retrieved on: 
Thursday, December 14, 2023
Climate change, Water quality, Consumer, Consumer economics, Clean Water Act, ACES, Environmental science, College, Water pollution, Weather, Journal, Concentrated animal feeding operation, University of Illinois Urbana-Champaign, Farm, Animal, Farmer, University of Wisconsin–Madison, Nutrient, Inflation, Interview, University, Human, Ammonia, Phosphorus, Water, Gulf of Mexico, Swimming, Soil, Economics, Environment, Mississippi River, Fertilizer, Agriculture, Dairy

MILWAUKEE, Dec. 14, 2023 /PRNewswire-PRWeb/ -- Nutrient runoff from agricultural production is a significant source of water pollution in the U.S., and climate change that produces extreme weather events is likely to exacerbate the problem. A new study from the University of Illinois Urbana-Champaign looks at how extreme rainfall impacts runoff and suggests possible mitigation strategies.

Key Points: 
  • A new study from the University of Illinois Urbana-Champaign looks at how extreme rainfall impacts runoff and suggests possible mitigation strategies.
  • They found spikes in nutrient concentrations immediately after extreme precipitation events, and the effect increased with the amount of precipitation.
  • "Conservation strategies are not necessarily cost-effective for producers, so we must ensure there are policies in place to support their implementation.
  • The paper, "The impact of extreme precipitation on nutrient runoff," is published in the Journal of the Agricultural and Applied Economics Association [doi.org/10.1002/jaa2.90].

P2 Science Announces Appointment of Oihana Elizalde as CEO

Retrieved on: 
Wednesday, December 13, 2023
Polymer science, Head, Oil, Science, Elizalde, Textile, Marketing, BASF, Growth, Doctor of Philosophy, Oihana Kortazar, Nature, Management, Phosphorus, Green, P2

WOODBRIDGE, Conn., Dec. 13, 2023 /PRNewswire-PRWeb/ -- Green chemistry company P2 Science announced today the appointment of Oihana Elizalde, PhD as Chief Executive Officer effective November 27, 2023.

Key Points: 
  • Green chemistry company P2 Science announced today the appointment of Oihana Elizalde, PhD as Chief Executive Officer effective November 27, 2023.
  • WOODBRIDGE, Conn., Dec. 13, 2023 /PRNewswire-PRWeb/ -- Green chemistry company P2 Science announced today the appointment of Oihana Elizalde, PhD as Chief Executive Officer effective November 27, 2023.
  • Elizalde said that "I am honored to join the talented team at P2 and lead this next phase of growth and expansion.
  • Elizalde said that "I am honored to join the talented team at P2 and lead this next phase of growth and expansion.

Duke Energy, Coastal Conservation Association Florida plant 500 mangroves at state park devastated by Hurricane Ian

Retrieved on: 
Tuesday, December 12, 2023
Carbon, Disaster, NYSE, Plant, Water quality, Duke Energy Florida, Nitrogen, Pass, Coastal Conservation Association, Hurricane Ian, Health, Nutrient, University, Delnor-Wiggins Pass State Park, Phosphorus, Water, Electricity, Power, Volunteering, CCA, Duke Energy, Canal, Aquaculture

Earlier today, more than 25 volunteers from Duke Energy Florida, Coastal Conservation Association (CCA) Florida, as well as special help from Lee County Electric Cooperative (LCEC), teamed up to lead the restoration by planting 500 red and black mangroves across a 4,400-square-foot portion of the park.

Key Points: 
  • Earlier today, more than 25 volunteers from Duke Energy Florida, Coastal Conservation Association (CCA) Florida, as well as special help from Lee County Electric Cooperative (LCEC), teamed up to lead the restoration by planting 500 red and black mangroves across a 4,400-square-foot portion of the park.
  • The mangroves were grown and donated by the Duke Energy Crystal River Mariculture Center, a company-owned-and-operated fish hatchery dedicated to environmental conservation, and CCA Florida.
  • Mangroves reduce coastal erosion caused by storm surges and improve water quality by absorbing excess nutrients like nitrogen and phosphorus.
  • "As a company, our work doesn't end when the restoration ends," said Melissa Seixas, Duke Energy Florida state president.